Form S-3 - Registration statement under Securities Act of 1933:
SEC Accession No. 0001213900-25-096190
Filing Date
2025-10-03
Accepted
2025-10-03 17:19:55
Documents
17
Reference 429
333-283212

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea0260171-s3_oruka.htm S-3 283222
2 OPINION OF DAVIS POLK & WARDWELL LLP ea026017101ex5-1_oruka.htm EX-5.1 13171
3 CONSENT OF PRICEWATERHOUSECOOPERS LLP, INDEPENDENT REGISTERED PUBLIC ACCOUNTING ea026017101ex23-1_oruka.htm EX-23.1 1554
4 FILING FEE TABLE ea026017101ex-fee_oruka.htm   iXBRL EX-FILING FEES 32125
5 GRAPHIC image_001.jpg GRAPHIC 4192
6 GRAPHIC ex5-1_001.jpg GRAPHIC 1758
  Complete submission text file 0001213900-25-096190.txt   492038

Data Files

Seq Description Document Type Size
19 EXTRACTED XBRL INSTANCE DOCUMENT ea026017101ex-fee_oruka_htm.xml XML 9991
Mailing Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025
Business Address 855 OAK GROVE AVE. SUITE 100 MENLO PARK CA 94025 650-606-7910
Oruka Therapeutics, Inc. (Filer) CIK: 0000907654 (see all company filings)

EIN.: 363855489 | State of Incorp.: DE | Fiscal Year End: 1231
Type: S-3 | Act: 33 | File No.: 333-290715 | Film No.: 251375000
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)